Confirmed Objective Response Rate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Confirmed Objective Response Rate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Confirmed Objective Response Rate Today - Breaking & Trending Today

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC

Published: September 10, 2023

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS®...

Source: prnewswire.com

Related Topics:

United StatesPuerto RicoUnited KingdomSouth KoreaUnited Arab EmiratesHong KongSaudi ArabiaMacau GeneralGreat BritainJeffreym ClarkeDavidm ReeseJessica AkopyanSpira AlJustin ClaeysDrug AdministrationAmerican Cancer SocietyBeigene LtdChemocentryx IncKyowa Kirin Co LtdEuropean UnionMost Sustainable CompaniesTeneobio IncExchange CommissionDuke Cancer Institute At UniversityPatients Treated

ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting - Press Release

Published: March 20, 2022

Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4%, including 5 Complete Responses; Updated Median Duration of Response of 6.9

Source: wiredprnews.com

Related Topics:

United StatesMirvetuximab SoravtansineAnna BerkenblitUrsula MatulonisRoche GroupHarvard Medical SchoolDana Farber Cancer InstituteSociety Of Gynecologic OncologyDivision Of Gynecologic OncologyImmunogen IncTrial Met Primary EndpointConfirmed Objective Response RateUpdated Median DurationDemonstrated Meaningful Anti Tumor ActivityConsistent SafetyFavorable TolerabilityHigh Platinum Resistant OvarianGynecologic OncologySenior Vice PresidentChief Medical OfficerPlatinum Resistant Ovarian CancerHigh Folate Receptor Alpha ExpressionScientific PlenaryMoly Meeting RoomWestin Phoenix